Zoster vaccine contains live, attenuated (weakened) varicella-zoster virus (VZV). Varicella-zoster causes chickenpox and then becomes dormant in nerves. VZV reactivates and causes herpes zoster (shingles or zoster) later in life (usually 60 years of age or older) when immunity against VZV declines. Zoster vaccine stimulates the immune system to develop immunity against VZV. The FDA approved zoster vaccine in May 2006.

Zostavax

GENERIC AVAILABLE: No

Yes

The most common adverse effects are:

• headaches,
• injection site swelling,
• itching,
• swelling,
• pain,
• warmth,
• bleeding, and
• bruising.

Some individuals may experience shingles or chickenpox-like rashes within 42 days after receiving zoster vaccine. Transmission of VZV virus from vaccinated individuals to other individuals occurs rarely.

Zoster vaccine is injected subcutaneously (under the skin) in the upper arm. The recommended dose is 0.65 ml.

In clinical studies, concomitant use of zoster vaccine and Pneumovax reduced the activity of zoster vaccine.

Zoster vaccine is not used for preventing shingles in women of child bearing age and should not be administered to pregnant women.

Zoster vaccine is not used for preventing shingles in nursing mothers.

What preparations of Zoster Vaccine Live (Shingles Vaccine) are available?

Powder for Injection: 0.65 ml

How should I keep Zoster Vaccine Live (Shingles Vaccine) stored?

Powder should be stored frozen at 15 C (5 F) or colder until ready to use. Diluent should be stored at room temperature (20 C - 25 C [68 F - 77 F]) or refrigerated at (2 C - 8 C [36 F - 46 F]).